Brain tumor pathology · 2011
Adult cerebellar glioblastoma cases have different characteristics from supratentorial glioblastoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Utsuki Satoshi, Oka Hidehiro, Miyajima Yoshiteru, Kijima Chihiro, Yasui Yoshie, Fujii Kiyotaka
Аннотация
This study is a histological and clinical investigation of four cases of cerebellar glioblastoma, a rare tumor. The cases included three males and one female, from 33 to 67 years in age (mean 49 years). Tumor resection, postoperative irradiation and chemotherapy were performed in all cases. Two patients died of local tumor recurrence after 14 and 27 months. Another patient relapsed after 10 months; however, after additional tumor resection and second line chemotherapy, she remains disease-free 41 months after the initial treatment. The fourth patient has not relapsed in the 6 months since initial treatment. The histopathology of all cases was glioblastoma with pseudopalisading necrosis. However, low-grade glioma histopathology was found in three patients. All glioblastomas were immunopositive for p53 and immunonegative for epidermal growth factor receptor (EGFR) and isocitrate dehydrogenase 1 (IDH1). These adult cerebellar glioblastoma cases had similar clinical and pathological characteristics, and had different characteristics compared with supratentorial glioblastomas.
Предметные рубрики MeSH
AdultAgedBiomarkers, TumorCerebellar NeoplasmsChemoradiotherapyCombined Modality TherapyErbB ReceptorsFemaleGlioblastomaHumansImmunohistochemistryIsocitrate DehydrogenaseMaleMiddle AgedNeoplasm Recurrence, LocalNeurosurgical ProceduresRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionSupratentorial NeoplasmsTreatment OutcomeTumor Suppressor Protein p53